8.2 Assent in Minors & Legally Authorized Representative (LAR) Requirements

Assent in Minors & Legally Authorized Representative (LAR) Requirements

Exam scope note: This section cites national regulations (for example US Code of Federal Regulations provisions) because they shape day-to-day practice. ACRP states the ACRP-CP exam is referenced only to ICH Guidelines and that no country-specific framework is tested. Treat those citations as professional context; the provision examined here is ICH E6(R3) Principle 2.1 and Annex 1 section 2.8, together with ICH E11(R1), which E6(R3) cites directly on assent from minors.

Quick Reference: When a prospective clinical trial subject lacks the legal or cognitive capacity to provide autonomous informed consent—such as a minor child or an incapacitated adult—special regulatory protections are activated. For adults lacking decision-making capacity, consent must be obtained from a Legally Authorized Representative (LAR) in accordance with state/local law (21 CFR 50.3(l) and the ICH E6(R3) Glossary). For pediatric subjects, research is governed by Subpart D regulations (21 CFR 50 Subpart D / 45 CFR 46 Subpart D), requiring Parental Permission (from one or both parents depending on risk-benefit category) paired with child Assent.

On the ACRP-CP (ACRP Certified Professional) exam, questions concerning LAR authority and pediatric research frequently test your mastery of surrogate hierarchies, parental permission thresholds, minor assent documentation, and the critical transition when a child turns 18 during active trial participation.

---

1. Legally Authorized Representatives (LAR): Definition & Authority

Regulatory Definition (21 CFR 50.3(l) & the ICH E6(R3) Glossary)

"An individual or judicial or other body authorized under applicable law to consent on behalf of a prospective subject to the subject's participation in the procedure(s) involved in the research."

┌───────────────────────────────────────────────────────────────────────────┐
│                      WHEN CAN AN LAR BE UTILIZED?                         │
├───────────────────────────────────────────────────────────────────────────┤
│  1. Cognitively impaired adults (e.g., advanced Alzheimer's disease)      │
│  2. Acutely incapacitated trauma / intensive care patients (ICU / coma)   │
│  3. Individuals with court-appointed legal guardians for medical decisions │
│  CRITICAL RULE: An LAR can NEVER be used to override a competent adult's  │
│  explicit refusal to participate in a clinical trial!                     │
└───────────────────────────────────────────────────────────────────────────┘

State Law Primacy & Surrogate Hierarchy

Federal regulations do not define who qualifies as an LAR; instead, they explicitly defer to applicable state and local law. Clinical research sites must follow their specific state's statutory hierarchy of surrogate decision-makers. A standard statutory hierarchy typically operates as follows:

1. Court-Appointed Legal Guardian (with specific healthcare decision authority)
   └── 2. Designated Healthcare Proxy / Durable Power of Attorney for Healthcare (DPOA)
       └── 3. Legal Spouse
           └── 4. Adult Children (majority agreement among available adult children)
               └── 5. Parents
                   └── 6. Adult Siblings
                       └── 7. Nearest Living Adult Relative

Exam Key Point: A general "Power of Attorney (POA) for Finances" does not grant authority to consent to clinical research. Only a Durable Power of Attorney for Healthcare (DPOA), a designated healthcare proxy, or a court-appointed guardianship specifically including medical decision-making empowers an individual to act as an LAR for clinical trials.

---

2. Pediatric Research Protections: Subpart D Categories

Children are classified as a vulnerable population because they lack legal capacity to consent and may be vulnerable to coercion. Federal regulations (21 CFR 50 Subpart D for FDA-regulated products and 45 CFR 46 Subpart D for HHS-funded research) divide pediatric research into four distinct risk-benefit categories:

Exceptions to the Two-Parent Permission Rule (Category 3 & 4):

Under 21 CFR 50.55(e)(2), permission from both parents is required under Categories 3 and 4 UNLESS:

1. One parent is deceased;
2. One parent is unknown;
3. One parent is incompetent;
4. One parent is not reasonably available (e.g., deployed overseas in military service without communication access); OR
5. Only one parent has legal custody of the child (e.g., sole legal custody granted by a court decree).

Exam Watchout: Divorced parents who share joint legal custody must both sign the parental permission form for Category 3 research. If one parent with joint custody refuses, the child cannot be enrolled, regardless of how enthusiastically the other parent agrees.

---

3. The Pediatric Assent Process & Age Thresholds

Defining Assent

Assent is defined as a child's affirmative agreement to participate in research. Mere failure to object or passive silence cannot be construed as assent.

┌───────────────────────────────────────────────────────────────────────────┐
│                       AGE-APPROPRIATE ASSENT TIERS                        │
├───────────────────────────────────────────────────────────────────────────┤
│  AGE < 7 YEARS:                                                           │
│  • Assent typically not required; child evaluated for developmental state │
│  • Parental permission alone governs enrollment                           │
├───────────────────────────────────────────────────────────────────────────┤
│  AGE 7 – 11 YEARS (Simple / Visual Assent):                              │
│  • Simplified 1-page form with plain language, illustrations, or comics   │
│  • Explains what will happen, what hurts (blood draws), and voluntariness  │
│  • Verbal or written assent documented per IRB policy                     │
├───────────────────────────────────────────────────────────────────────────┤
│  AGE 12 – 17 YEARS (Adolescent Assent):                                   │
│  • More comprehensive written document describing trial rationale,       │
│    randomization, side effects, study visit schedule, and right to stop   │
│  • Signed and dated written assent by the adolescent                      │
├───────────────────────────────────────────────────────────────────────────┤
│  AGE 18+ YEARS (Legal Adulthood):                                         │
│  • Full adult Informed Consent Form signed by the participant             │
└───────────────────────────────────────────────────────────────────────────┘

When Can the IRB Waive Pediatric Assent?

Under 21 CFR 50.55(c), the IRB may waive the assent requirement if:

1. The capability of some or all of the children is so limited that they cannot reasonably be consulted (e.g., severe developmental delay, acute coma);
2. The intervention or procedure involved in the research holds out a prospect of direct benefit that is important to the health or well-being of the child and is available only in the context of the research (e.g., life-saving pediatric oncology protocol with no commercial alternative); OR
3. The research meets standard minimal-risk waiver criteria under 45 CFR 46.116.

Pediatric Dissent vs. Parental Permission

If a clinical trial involves no prospect of direct benefit (e.g., Category 1 or Category 3 pharmacokinetic studies) and an assenting-age child dissents (refuses to participate or says "no"), the child's dissent must be respected. Parents cannot force a child to participate in non-beneficial research.

---

4. Emancipated Minors vs. Mature Minors

Not all individuals under 18 years of age require parental permission. State law establishes critical legal exemptions:

┌───────────────────────────────────────────────────────────────────────────┐
│                     SPECIAL MINOR LEGAL STATUSES                          │
├───────────────────────────────────────────────────────────────────────────┤
│  1. EMANCIPATED MINORS:                                                   │
│     • Recognized by court declaration, legal marriage, active military    │
│       enlistment, or complete financial self-sufficiency (per state law). │
│     • Possess FULL legal authority of an adult; consent for themselves.   │
│     • NO parental permission is required or permitted.                    │
├───────────────────────────────────────────────────────────────────────────┤
│  2. MATURE MINOR DOCTRINE / STATUTORY CONSENT:                            │
│     • Specific state laws allowing minors to consent independently for    │
│       certain medical treatments: STI testing/treatment, contraception,   │
│       substance abuse treatment, and outpatient mental health.            │
│     • In research studying these specific conditions, IRBs may waive      │
│       parental permission if obtaining parental permission would breach   │
│       minor confidentiality and pose harm (45 CFR 46.408(c)).             │
└───────────────────────────────────────────────────────────────────────────┘

Wards of the State (21 CFR 50.56 / 45 CFR 46.409)

Children who are wards of the state or any other agency, institution, or entity can be included in research approved under Category 3 (21 CFR 50.53) or Category 4 (21 CFR 50.54) ONLY IF such research is:

1. Related to their status as wards; OR
2. Conducted in schools, camps, hospitals, institutions, or similar settings in which the majority of children involved as subjects are not wards.
3. Independent Advocate Mandate: The IRB must require the appointment of an independent Advocate for each child who is a ward, who acts in addition to any other individual acting on behalf of the child as guardian or in loco parentis.

---

5. Transition of Minors Who Reach the Legal Age of Majority (Turning 18)

One of the most frequently missed operational requirements in longitudinal pediatric trials occurs when a child reaches the legal age of majority (18 years old) while actively participating in a clinical trial.

┌───────────────────────────────────────────────────────────────────────────┐
│                   PEDIATRIC TRANSITION AT 18TH BIRTHDAY                   │
├───────────────────────────────────────────────────────────────────────────┤
│  • Legal Reality: At age 18, parental permission AUTOMATICALLY EXPIRES.   │
│  • Operational Mandate: The subject is now a legal adult.                 │
│  • Required Action: The site must RE-CONSENT the participant using the    │
│    IRB-approved adult Informed Consent Form at the very next contact.     │
│  • If Not Re-Consented: No further study interventions, blood draws, or   │
│    active data collection can occur until adult consent is executed.      │
└───────────────────────────────────────────────────────────────────────────┘

OHRP & FDA Regulatory Consensus on Aging-Up:

• Informed consent is an ongoing process. Parental permission is legally valid only while the individual is a minor under state law.
• As soon as the subject turns 18, the investigator must seek and obtain autonomous informed consent from the now-adult participant using the standard adult ICF.
• If the subject chooses not to sign the adult ICF, they have exercised their autonomous right to withdraw, and no further study-related procedures or interventions may be performed on that individual.

---

6. Realistic Clinical Scenario & ACRP-CP Critical Analysis

Scenario: A 15-year-old high school student with moderate persistent asthma is evaluated for enrollment in a Phase III trial evaluating an investigational biologic. The protocol is classified by the IRB under 21 CFR 50.53 / 45 CFR 46.406 (Category 3: Greater than minimal risk with no direct benefit, but offering generalizable knowledge) because it involves invasive bronchoscopy biopsies without therapeutic intent.

The student's mother attends the screening visit, provides written parental permission, and expresses great enthusiasm. The student signs the adolescent assent form. The parents are divorced with joint legal custody. The father lives two hours away and, when reached by phone, states: "I do not want my child undergoing invasive lung biopsies for research. I refuse to sign."

ACRP-CP Critical Evaluation & Decision Path:

1. Regulatory Mandate (Subpart D Category 3): Under 21 CFR 50.53 and 50.55(e)(2), Category 3 research strictly mandates permission from BOTH parents unless one is deceased, unknown, incompetent, or not reasonably available, or one parent has sole legal custody.
2. Legal Custody Status: Because the parents share joint legal custody, the father possesses legal standing.
3. Father Availability: Living two hours away and communicating by phone confirms the father is "reasonably available" and competent.
4. Compliance Outcome: Because the father refuses to give permission, the requirement for two-parent permission cannot be met. The site cannot enroll the child, and proceeding with enrollment based on the mother's signature alone is a major regulatory violation.